SpringWorks Therapeutics Inc - ESG Rating & Company Profile powered by AI
This ESG rating for SpringWorks Therapeutics Inc indicates its reporting of the United Nations Sustainable Development Goals. The ESG score includes 17 UN Sustainable Development Goals including: 'Good Health & Wellbeing', 'Industry, Innovation & Infrastructure' and 'Partnerships for the Goals'. If you are employed by SpringWorks Therapeutics Inc and you would like to licence your Sustainability aseessment, please contact us.
SpringWorks Therapeutics Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 2.9; made up of an environmental score of 1.3, social score of 3.4 and governance score of 4.0.
2.9
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1336 | SyneuRx International (Taiwan) Corp | 3.0 | Medium |
1336 | Sensorion SA | 3.0 | Medium |
1353 | SpringWorks Therapeutics Inc | 2.9 | Medium |
1353 | Caribou Biosciences Inc | 2.9 | Medium |
1353 | Checkmate Pharmaceuticals Inc | 2.9 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does SpringWorks Therapeutics Inc have an accelerator or VC vehicle to help deliver innovation?
Does SpringWorks Therapeutics Inc disclose current and historical energy intensity?
Does SpringWorks Therapeutics Inc report the average age of the workforce?
Does SpringWorks Therapeutics Inc reference operational or capital allocation in relation to climate change?
Does SpringWorks Therapeutics Inc disclose its ethnicity pay gap?
Does SpringWorks Therapeutics Inc disclose cybersecurity risks?
Does SpringWorks Therapeutics Inc offer flexible work?
Does SpringWorks Therapeutics Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does SpringWorks Therapeutics Inc disclose the number of employees in R&D functions?
Does SpringWorks Therapeutics Inc conduct supply chain audits?
Does SpringWorks Therapeutics Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does SpringWorks Therapeutics Inc conduct 360 degree staff reviews?
Does SpringWorks Therapeutics Inc disclose the individual responsible for D&I?
Does SpringWorks Therapeutics Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does SpringWorks Therapeutics Inc disclose current and / or historical scope 2 emissions?
Does SpringWorks Therapeutics Inc disclose water use targets?
Does SpringWorks Therapeutics Inc have careers partnerships with academic institutions?
Did SpringWorks Therapeutics Inc have a product recall in the last two years?
Does SpringWorks Therapeutics Inc disclose incidents of discrimination?
Does SpringWorks Therapeutics Inc allow for Work Councils/Collective Agreements to be formed?
Has SpringWorks Therapeutics Inc issued a profit warning in the past 24 months?
Does SpringWorks Therapeutics Inc disclose parental leave metrics?
Does SpringWorks Therapeutics Inc disclose climate scenario or pathway analysis?
Does SpringWorks Therapeutics Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does SpringWorks Therapeutics Inc disclose the pay ratio of women to men?
Does SpringWorks Therapeutics Inc support suppliers with sustainability related research and development?
Does SpringWorks Therapeutics Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does SpringWorks Therapeutics Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is SpringWorks Therapeutics Inc involved in embryonic stem cell research?
Does SpringWorks Therapeutics Inc disclose GHG and Air Emissions intensity?
Does SpringWorks Therapeutics Inc disclose its waste policy?
Does SpringWorks Therapeutics Inc report according to TCFD requirements?
Does SpringWorks Therapeutics Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does SpringWorks Therapeutics Inc disclose energy use targets?
Does SpringWorks Therapeutics Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does SpringWorks Therapeutics Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for SpringWorks Therapeutics Inc
These potential risks are based on the size, segment and geographies of the company.
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.